 |
|
|
| |
Antiviral Efficacy of the Once Daily NS3 Protease Inhibitor GS-9451, the Non-Nucleoside NS5B Inhibitor Tegobuvir (GS-9190), and Pegylated Interferon + Ribavirin in Treatment-Naïve Patients With Genotype 1 Hepatitis C Infection
|
| |
| |
Reported by Jules Levin
EASL 2013 April 26 Amsterdam, the Netherlands
Stanislas Pol1, Maciej Jablkowski2, James D. Trenkle3, Bittoo Kanwar3, B. Nebiyou Bekele3, G. Mani Subramanian3, John G. McHutchison3, Steven L. Flamm4, Andrew J. Muir5
1University of Paris Descartes, Hospital Beaujon, Clichy, France; 2Medical University of Lodz, Poland; 3Gilead Sciences, Inc., Foster City, CA, USA; 4Northwestern Feinberg School of Medicine, Chicago, IL, USA; 5Duke Clinical Research Institute, Duke University, Durham, NC, USA
|
| |
|
|
|
|
|
